Spyre Therapeutics, Inc. (SYRE)
| Market Cap | 5.92B |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -126.54M |
| Shares Out | 86.26M |
| EPS (ttm) | -1.98 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,070,323 |
| Open | 72.10 |
| Previous Close | 71.90 |
| Day's Range | 68.20 - 73.96 |
| 52-Week Range | 12.29 - 75.00 |
| Beta | 2.94 |
| Analysts | Strong Buy |
| Price Target | 85.08 (+23.97%) |
| Earnings Date | May 8, 2026 |
About SYRE
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the α4β7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn’s disease); and SPY002 and SPY072 – anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also develo... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for SYRE stock is "Strong Buy." The 12-month stock price target is $85.08, which is an increase of 23.97% from the latest price.
News
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million
WALTHAM, Mass., April 16, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and anti...
Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock
WALTHAM, Mass., April 14, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineeri...
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
WALTHAM, Mass., April 13, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineeri...
Spyre Therapeutics Breaks Higher On Positive Data From Ulcerative Colitis Drug
• Spyre Therapeutics stock is approaching key resistance levels. Why is SYRE stock breaking out?
Spyre Therapeutics Transcript: Study result
SPY001 demonstrated strong efficacy and safety in the SKYLINE Part A induction study for ulcerative colitis, achieving high rates of clinical remission and endoscopic improvement. Results exceeded benchmarks from precedent trials, supporting SPY001 as a promising monotherapy and combination backbone, with further global studies underway.
Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients
SPY001 met its primary endpoint with a statistically significant reduction of 9.2 points (p
Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026
WALTHAM, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefi...
Spyre Therapeutics Announces Grants of Inducement Awards
WALTHAM, Mass., April 03, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE) (the “Company” or “Spyre”), a clinical-stage biotechnology company pioneering long-acting antibodies and anti...
Spyre Therapeutics Transcript: Leerink Global Healthcare Conference 2026
The company is advancing optimized biologics for IBD and rheumatology, with six phase II readouts expected this year. Combination therapies are prioritized for their safety and efficacy, and a seamless trial design accelerates development. Commercial strategy is being shaped by upcoming data and market access considerations.
Spyre Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference
The company is advancing optimized monotherapies and combinations for IBD and rheumatic diseases, aiming to break efficacy ceilings with novel, long-acting agents. Multiple phase II readouts are expected in 2024, with strong funding and a platform trial design supporting rapid progress.
Spyre Therapeutics to Participate in Upcoming March Investor Conferences
WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefin...
Spyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
On track for 6 proof-of-concept readouts in 2026 across the SKYLINE and SKYWAY Phase 2 trials Part A readouts from SKYLINE platform trial in ulcerative colitis ("UC") expected to begin in the second ...
Spyre Therapeutics Poised for Transformational 2026 With Six Expected Proof-of-Concept Readouts Beginning in Q2
“6 in '26” expected proof-of-concept (POC) readouts across SKYLINE and SKYWAY trials SKYLINE platform trial in ulcerative colitis (UC) recruiting faster than expected with SPY001 enrollment complete a...
Spyre Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference
Combination therapies are being developed as single-shot co-formulations, with efficacy as the primary goal and objective endpoints like RHI used for assessment. Key trial readouts are expected next year, with expansion planned into arthritis and Crohn's disease indications.
Spyre Therapeutics Transcript: Jefferies London Healthcare Conference 2025
The team is advancing phase II antibody therapies for IBD and rheumatic diseases, focusing on combination products with optimized efficacy and safety. Their robust clinical design and co-formulation technology aim to set new standards in remission rates and convenience, with upcoming data expected to validate their approach.
Spyre Therapeutics Transcript: Stifel 2025 Healthcare Conference
Long-acting antibodies targeting IBD and rheumatic diseases are advancing, with a focus on combination therapies for superior efficacy and convenience. Multiple phase II readouts are expected next year, supported by strong financials and a flexible strategic approach.
Spyre Therapeutics Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference
Two major phase II trials are advancing long-acting biologics in IBD and rheumatic diseases, with six key readouts expected next year. The strategy emphasizes differentiated co-formulations, aiming for superior efficacy and convenience, supported by strong financials and a robust competitive position.
Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Reported positive interim Phase 1 results for SPY003, a next-generation anti-IL-23 antibody, demonstrating the molecule was well-tolerated and exhibited an ~85-day half-life supporting quarterly or tw...
Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody
SPY003 was well tolerated and exhibited an ~85-day half-life, supporting potential quarterly or twice annual maintenance dosing
Spyre Therapeutics Announces Poster Presentations at American College of Rheumatology (ACR) Convergence 2025
WALTHAM, Mass., Oct. 24, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefin...
Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares for Gross Proceeds of $316.2 Million
WALTHAM, Mass., Oct. 15, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineerin...
Spyre Therapeutics Announces Pricing of $275.0 Million Public Offering of Common Stock
WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineerin...
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded Warrants
WALTHAM, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (“Spyre” or the “Company”) (Nasdaq: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineerin...
Spyre Therapeutics Announces Poster Presentations at United European Gastroenterology Week (UEGW) 2025
WALTHAM, Mass., Oct. 05, 2025 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company advancing best-in-class antibody engineering, dose optimization, and r...
Spyre Therapeutics Transcript: Stifel Virtual Immunology and Inflammation Forum
Focused on unmet needs in autoimmune diseases, the company is advancing phase II trials with co-formulated antibody combinations and expects nine major readouts over two years. Strong financials support operations through 2028, with flexibility for future partnerships or independent advancement.